Meeting
2011 ASCO Annual Meeting
Efficacy endpoints of RTOG 0247: A randomized phase II study of neoadjuvant capecitabine (C) and irinotecan (I) or C and oxaliplatin (O) with concurrent radiation therapy (RT) for locally advanced rectal cancer.
Authors
S. J. Wong
Medical College of Wisconsin, Milwaukee, WI
S. J. Wong , J. Moughan , N. J. Meropol , P. R. Anne , L. A. Kachnic , A. Rashid , J. C. Watson , E. P. Mitchell , J. Pollock , M. G. Haddock , B. Erickson , C. G. Willett
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT00081289
Citation
J Clin Oncol 29: 2011 (suppl; abstr 3517)
Abstract #
3517
Poster Bd #
6
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer: A single center phase II trial.
First Author: Wen Zhang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Total neoadjuvant therapy (TnT) with FOLFOX followed by short course radiation in locally advanced rectal cancer: A phase II study.
First Author: Janice Zhao
Poster
2024 ASCO Gastrointestinal Cancers Symposium
FOLFIRINOX plus high intensity focused ultrasound for locally advanced/borderline resectable pancreatic ductal adenocarcinoma: A prospective single arm phase II trial.
First Author: Dong Ho Lee
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando